Keros Therapeutics Stock Income Statements

Keros Therapeutics Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Operating Profit

Net Income

Keros Therapeutics Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31

revenue:
service and other revenue	18,168,000	15,891,000	42,000	388,000	37,000	83,000
license revenue		195,355,000													25,000		100,000
total revenue	18,168,000	211,246,000	3,042,000	388,000	37,000	83,000	143,000	8,000							20,000,000		100,000
yoy	49002.70%	254413.25%	2027.27%	4750.00%
qoq	-91.40%	6844.31%	684.02%	948.65%	-55.42%	-41.96%	1687.50%
operating expenses:
research and development	-43,503,000	-48,709,000	-45,631,000	-49,225,000	-40,515,000	-38,258,000	-37,493,000	-34,140,000	-32,534,000	-31,091,000	-24,867,000	-21,039,000	-23,281,000	-18,078,000	-18,833,000	-14,832,000	-9,983,000	-11,495,000	-9,674,000	-8,395,000	-7,264,000	-8,527,000
general and administrative	-14,482,000	-10,497,000	-10,665,000	-9,820,000	-9,961,000	-10,308,000	-9,105,000	-9,148,000	-8,803,000	-7,778,000	-7,093,000	-6,937,000	-7,447,000	-6,048,000	-6,033,000	-5,365,000	-5,658,000	-4,274,000	-3,617,000	-3,553,000	-3,650,000	-1,977,000
total operating expenses	-57,985,000	-59,206,000	-56,296,000	-59,045,000	-50,476,000	-48,566,000	-46,598,000	-43,288,000	-41,337,000	-38,869,000	-31,960,000	-27,976,000	-30,728,000	-24,126,000	-24,866,000	-20,197,000	-15,641,000	-15,769,000	-13,291,000	-11,948,000	-10,914,000	-10,504,000
income from operations	-39,817,000	152,040,000	-53,254,000	-58,657,000	-50,439,000	-48,483,000	-46,455,000	-43,280,000	-41,337,000	-38,869,000	-31,960,000	-27,976,000	-30,728,000	-24,126,000	-4,866,000	-20,197,000	-15,541,000	-15,769,000	-13,291,000	-11,948,000	-10,914,000	-10,504,000
yoy	-21.06%	-413.59%	14.64%	35.53%	22.02%	24.73%	45.35%	54.70%	34.53%	61.11%	556.80%	38.52%	97.72%	53.00%	-63.39%	69.04%	42.40%	50.12%
qoq	-126.19%	-385.50%	-9.21%	16.29%	4.03%	4.37%	7.34%	4.70%	6.35%	21.62%	14.24%	-8.96%	27.36%	395.81%	-75.91%	29.96%	-1.45%	18.64%	11.24%	9.47%	3.90%
operating margin %	-219.16%	71.97%	-1750.62%	-15117.78%	-136321.62%	-58413.25%	-32486.01%	-541000.00%							-24.33%		-15541.00%
other income	-221,000	-338,000	-229,000	-92,000	-196,000	-437,000	-10,943,000	3,840,000	3,832,000	3,065,000	2,242,000	762,000	86,000	-59,000	-74,000	-137,000	-80,000	-65,000	156,000	-86,000	158,000	-68,000
dividend income	7,120,000	6,792,000	6,519,000	5,793,000	5,378,000	5,806,000
total other income	6,899,000	6,454,000	7,528,000	5,701,000	5,182,000	5,369,000	6,212,000	3,840,000	3,832,000	3,065,000	2,242,000	4,467,000	3,462,000	-60,000	-75,000	-138,000	-81,000	-66,000	2,615,000	-88,000	157,000	-1,560,000
income before income taxes	-32,918,000	158,494,000									-29,718,000	-23,509,000	-27,266,000	-24,186,000	-4,941,000	-20,335,000	-15,622,000	-15,835,000	-10,676,000	-12,036,000	-10,757,000	-12,064,000
income tax benefit	2,222,000														-1,999,000	38,000		-50,000				172,000
net income	-30,696,000	148,451,000	-46,026,000	-52,956,000	-45,257,000	-43,114,000	-40,243,000	-39,440,000	-37,505,000	-35,804,000	-29,718,000	-23,509,000	-27,266,000	-24,186,000	-6,940,000	-20,297,000	-15,622,000	-15,885,000	-10,676,000	-12,036,000	-10,757,000	-11,892,000
yoy	-32.17%	-444.32%	14.37%	34.27%	20.67%	20.42%	35.42%	67.77%	37.55%	48.04%	328.21%	15.82%	74.54%	52.26%	-34.99%	68.64%	45.23%	33.58%
qoq	-120.68%	-422.54%	-13.09%	17.01%	4.97%	7.13%	2.04%	5.16%	4.75%	20.48%	26.41%	-13.78%	12.73%	248.50%	-65.81%	29.93%	-1.66%	48.79%	-11.30%	11.89%	-9.54%
net income margin %	-168.96%	70.27%	-1513.02%	-13648.45%	-122316.22%	-51944.58%	-28141.96%	-493000.00%							-34.70%		-15622.00%
net income attributable to common stockholders — basic and diluted	-30,696,000	148,451,000
weighted-average shares of common stock outstanding — basic	40,612,907,000	40,559,355,000
weighted-average shares of common stock outstanding — diluted	40,612,907,000	41,021,325,000
net income per share	-0.76	3.66	-1.12	-1.41	-1.25	-1.21	-1.34	-1.33	-1.27	-1.26	-1.1	-0.92	-1.13	-1.01	-0.3	-0.87	-0.67	-0.68	-0.28	-0.6	-0.62	-5.11
income tax provision		-10,043,000
net income attributable to common stockholders—basic and diluted			-46,026,000	-52,956,000	-45,257,000	-43,114,000	-40,243,000	-39,440,000	-37,505,000	-35,804,000	-29,718,000	-23,509,000	-27,266,000	-24,186,000	-6,940,000	-20,297,000	-15,622,000	-15,885,000	-9,664,000	-12,036,000	-10,963,000	-12,698,000
weighted-average common stock outstanding—basic and diluted			37,437,652	37,590,727	36,103,187	35,685,422	29,447,119	29,668,247	29,602,458	28,369,453	25,241,030	25,549,701	24,053,977	23,993,698	23,333,914	23,362,237	23,305,673	23,229,794	15,506,397	20,175,883	17,623,994	2,484,057
service revenue							2,000	8,000
interest expense														-1,000	-1,000	-1,000	-1,000	-1,000	-1,000	-2,000	-1,000	-2,000
research and development incentive income												3,705,000	3,376,000
change in fair value of preferred stock tranche obligation																						-1,490,000
research collaboration revenue
other income, net:

We provide you with 20 years income statements for Keros Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Keros Therapeutics stock. Explore the full financial landscape of Keros Therapeutics stock with our expertly curated income statements.

The information provided in this report about Keros Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.